

## **LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARDBOARD BOX (1x1ml only)**  
**PLASTIC BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Versiguard Rabies, suspension for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

One dose (1 ml) contains:  
Inactivated rabies virus min. 5 IU/ml

**3. PHARMACEUTICAL FORM**

Suspension for injection

**4. PACKAGE SIZE**

1 x 1 ml  
10 x 1 ml  
10 x 10 ml

**5. TARGET SPECIES**

Dogs, cats, cattle, pigs, sheep, goats, horses and ferrets

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Dogs: SC.

Cats, ferrets, cattle, pigs, sheep, goats, horses: SC or IM.

**8. WITHDRAWAL PERIOD(S)**

Dogs, cats, ferrets: Not applicable.

Withdrawal period for cattle, pigs, sheep, goats, horses: Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Accidental self-injection is dangerous.

**10. EXPIRY DATE**

EXP 00 (month) / 0000 (year)

Once broached use within 10 hours.

**11. SPECIAL STORAGE CONDITIONS**

Store in a refrigerator.

Do not freeze

Protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 42058/4194

**17. MANUFACTURER’S BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**GLASS VIALS (1 ml)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Versiguard Rabies, suspension for injection

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Inactivated rabies virus min. 5 IU/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

1 ml

**4. ROUTE(S) OF ADMINISTRATION**

SC/IM (dogs SC)

**5. WITHDRAWAL PERIOD(S)**

**6. BATCH NUMBER**

Lot {number}

**7. EXPIRY DATE**

EXP 00 (month) / 0000 (year)

**8. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**GLASS VIALS (10 ml)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Versiguard Rabies, suspension for injection

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Inactivated rabies virus min. 5 IU/ml, aluminium hydroxide 2.0 mg/ml, thiomersal 0.1 mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

10 ml

**4. ROUTE(S) OF ADMINISTRATION**

Dogs: SC.  
Other species: SC / IM.

**5. WITHDRAWAL PERIOD(S)**

Dogs, cats, ferrets: Not applicable.  
Withdrawal period for cattle, pigs, sheep, goats, horses: Zero days.

**6. BATCH NUMBER**

Lot{number}

**7. EXPIRY DATE**

EXP 00 (month) / 0000 (year)  
Once broached use within 10 hours.

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **B. PACKAGE LEAFLET**





#### **4. INDICATION(S)**

For the active immunization of dogs, cats, cattle, pigs, sheep, goats, horses and ferrets (12 weeks of age and older) to prevent infection and mortality caused by rabies virus.

Onset of immunity: 14–21 days after primary vaccination.

Duration of immunity:

Dogs: At least three years following the primary vaccination course.

Cats, cattle, pigs, sheep, goats, horses and ferrets: At least one year after primary vaccination, and two years after booster vaccinations.

#### **5. CONTRAINDICATIONS**

Do not use in animals that are showing signs of rabies or that are suspected of being infected with rabies virus.

Do not use in cases of hypersensitivity to the adjuvant or to any of the excipients.

#### **6. ADVERSE REACTIONS**

A transient swelling may occur at the injection site following subcutaneous administration in all target species in very rare cases. The swelling may reach a maximum diameter of up to 10 mm, and in rare cases be associated with mild discomfort. These reactions usually resolve within 10 days.

Transient mild pain (which in rare cases may be associated with swelling) at the site of injection following intramuscular administration in any other target species than dogs may very rarely occur. The swelling may reach a maximum diameter of up to 2 cm. These reactions usually resolve within 7 days.

Hypersensitivity reactions may occur very rarely. If such a reaction occurs, appropriate treatment should be administered without delay.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

#### **7. TARGET SPECIES**

Dogs, cats, cattle, pigs, sheep, goats, horses and ferrets.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Dogs: Administer by subcutaneous injection.

All other species: Administer by subcutaneous or intramuscular injection.

### Dosage:

A single dose inoculation of 1 ml is sufficient irrespective of age, weight or breed of animal.

### Primary vaccination:

Animals of all target species can be vaccinated from 12 weeks of age.

Primary vaccination is with a single dose of vaccine.

### Revaccination:

**Dogs:** A single dose of Versiguard Rabies should be given every 3 years. Antibody titres drop over the course of the 3-year duration of immunity, although dogs are protected when challenged. In case of travelling to risk areas or outside the EU, veterinary surgeons may wish to give additional rabies vaccinations to ensure that the vaccinated dogs have an antibody titre  $\geq 0.5$  IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres  $\geq 0.5$  IU/ml).

**Cats, cattle, pigs, sheep, goats, horses and ferrets:** Animals should be revaccinated with one dose of vaccine 1 year after primary vaccination.

After the first booster vaccination (administered 1 year after primary vaccination), animals should be revaccinated every 2 years with one dose of vaccine.

### Use as solvent for the Versican Plus range

The contents of a single vial of Versican Plus vaccine should be reconstituted with the contents of a single vial of Versiguard Rabies (instead of the solvent). Once mixed, the contents of the vial should appear a pink/red or yellowish colour with a slight opalescence. The mixed vaccines should be injected immediately via the subcutaneous route.

### Co-administration with Vanguard canine range

To mix both products, Vanguard vaccines should be reconstituted according to their SPCs. The reconstituted vial will be well shaken and then mixed with 1 ml of Versiguard Rabies either in the Versiguard Rabies vial or the syringe. Versiguard Rabies will be well shaken before use. The mixed vaccines will be gently shaken and then administered immediately by subcutaneous injection.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Shake the vial before use.

## **10. WITHDRAWAL PERIOD(S)**

Dogs, cats, ferrets: Not applicable.  
Cattle, pigs, sheep, goats, horses: Zero days.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.  
Store in a refrigerator (2 °C – 8 °C).  
Do not freeze.  
Protect from light.  
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.  
Shelf life after first opening the container: 10 hours.

## **12. SPECIAL WARNING(S)**

Special warnings for each target species:  
Vaccinate healthy animals only.

Special precautions for use in animals:  
Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Can be used during pregnancy.

The vaccine has not been extensively tested in lactating animals. However, the limited data that are available indicate that administration of the vaccine to lactating animals will not be associated with an increased incidence of adverse reactions.

Interaction with other medicinal products and other forms of interaction:

Dogs

Safety and efficacy data are available which demonstrate that this vaccine can be administered subcutaneously in dogs on the same day as any other vaccine from the Vanguard range (Vanguard 7, Vanguard Plus 7, Vanguard Plus 5, Vanguard Plus 5L, Vanguard Pup, Vanguard Puppy, Vanguard CPV, Vanguard CPV +L, Vanguard DA2Pi, Vanguard DA2Pi+L, Vanguard Lepto ci where approved), either mixed or at different sites. The duration of immunity for the Vanguard range when used with Versiguard Rabies has not been established.

After concurrent or mixed administration of Versiguard Rabies and Vanguard canine range, vaccinated dogs may have a transient swelling (up to 6 cm) at the injection site and a transient swelling of the sub-mandibular and/or pre-scapular lymph nodes at the injection site 4 hours after vaccination. These signs resolve within 24 hours.

Safety and efficacy data are available which demonstrate that this vaccine can also be used as solvent for the live vaccines of the Versican Plus range (Versican Plus DHPPi, DHP, DP, P and Pi) and administered subcutaneously in dogs. After mixed administration with the Versican Plus range vaccinated dogs may commonly have a transient swelling (up to 5 cm) at the injection site. The swelling can occasionally be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination. In rare cases gastrointestinal signs such as diarrhoea and vomiting or anorexia and decreased activity are possible.

Other target species:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

Overdose (symptoms, emergency procedures, antidotes):

Local reactions after subcutaneous vaccination with an overdose tended to larger (up to 12 mm in diameter) than after a standard dose.

Incompatibilities:

Do not mix with any other veterinary medicinal product other than vaccines of the Vanguard range containing CDV, CAV, CPV, CPiV and *Leptospira* or Versican Plus range containing CDV, CAV, CPV and/or CPiV.

National rabies control legislation may require different vaccination programmes to that recommended (e. g., more frequent vaccination) or may restrict rabies vaccination to particular target species.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

December 2022

**15. OTHER INFORMATION**

The vaccine is supplied in type I (1 ml, 10 ml) glass vials complying with Ph. Eur., sealed with a bromobutyl rubber stopper and aluminium cap.

Cardboard box of 1 vial of 1 ml.

Plastic box of 10 vials of 1 ml or 10 ml.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder given below.

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP.

A handwritten signature in black ink, appearing to read 'Dennett', written in a cursive style.

Approved: 07 December 2022